IschemiaDECIDE-GoldNCT02178904
Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques
An observational study of Ischemia, run by Weill Medical College of Cornell University at 5 sites in United States.
Trial summary
The purpose of this study is determine the diagnostic performance of dual energy computed tomography perfusion for non-invasive assessment of the hemodynamic significance of coronary stenosis, as compared to a direct measurement of fraction flow reserve during cardiac catheterization as a reference standard. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemia
- What is being tested?
- CT and stress test
- Type of treatment
- Surgery or procedure
- How many people
- 156 participants
- Where
- 5 sitesUnited States
- Study dates
- Mar 2014to 10 Jan 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Hospitals in Argentina, Beijing, Seattle, Vancouver, New York
Who may be able to join
- Age ≥ 18 years
- Patients provide written informed consent
- Patients scheduled to undergo clinically-indicated non-emergent invasive coronary angiography
- suspected coronary artery disease
Who cannot join
- Suspicion of acute coronary syndrome (acute myocardial infarction and unstable angina)
- Recent prior myocardial infarction within 40 days of ICA
- Known complex congenital heart disease
- Significant arrhythmia or tachycardia
- Impaired chronic renal function (serum creatinine > 1.5 mg/dl or GFR < 30 ml/min)
- Patients with known anaphylactic allergy to iodinated contrast
Show all 10Show fewer
- Pregnancy or unknown pregnancy status
- Contraindication to adenosine, including 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome; severe hypotension, severe asthma, severe COPD or bronchodilator-dependent COPD
- Patient requires an emergent procedure
- Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure <90 mmHg, and severe congestive heart failure (NYHA III or IV) or acute pulmonary edema
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
Medical University of South Carolina
Charleston, South Carolina, 29425
Wexner Medical Center, The Ohio State University Medical Center
Columbus, Ohio, 43210
Weill Cornell Medical College
New York, New York, 10021
Midwest Heart and Vascular Specialists
Overland Park, Kansas, 66215
University of Washington
Seattle, Washington, 98195
About this study
Official title: Dual Energy Computed Tomography for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques
The purpose of this study is determine the diagnostic performance of dual energy computed tomography perfusion for non-invasive assessment of the hemodynamic significance of coronary stenosis, as compared to a direct measurement of fraction flow reserve during cardiac catheterization as a reference standard.
The overall objective of the present study is to determine the diagnostic performance of dual energy computed tomography perfusion for non-invasive assessment of the hemodynamic significance of coronary stenosis, as compared to direct measurement of fraction flow reserve during cardiac catheterization as a reference standard.
Read the detailed description
Coronary artery disease is the leading cause of morbidity and mortality in the United States. At present, professional guidelines endorse the use of an array of non-invasive tests for patients with suspected coronary artery disease, which are limited to one of two approaches: 1) physiologic demonstration of ischemia by functional stress testing or 2) anatomic visualization of stenosis by coronary computed tomographic angiography.
Stress test for physiologic assessment of coronary disease is performed most commonly with the prognostic value unsurpassed by other non-invasive tests, with risk of cardiac events escalating exponentially with increasing inducible hypoperfusion. However, despite its high reported performance, the "real world" accuracy of stress test is less sanguine and demonstrates generally poor discrimination of specific vessels that accommodate coronary lesions that cause ischemia. These findings have encouraged the adoption of other stress tests, such as positron emission tomography, which offers reliable attenuation correction, increased count sensitivity, lower radiation dose and enhanced diagnostic performance. Positron emission tomography also enables measures of absolute myocardial blood flow.
Coronary computed tomographic angiography is an alternative test that evaluates coronary disease by direct anatomic visualization of stenoses in a manner similar to cardiac catheterization. Similarly, when employing invasive fractional flow reserve to identify ischemia, high-grade stenoses observed by computed tomography are causal of ischemia less than half of the time.
Multicenter randomized trial data examining invasive methods have demonstrated that a combined anatomic-physiologic approach by catheterization with fractional flow reserve improves identification of patients who may benefit from revascularization, by restricting revascularization to those with high-grade stenoses that specifically cause ischemia. Nevertheless, the combination of catheterization with fractional flow reserve is invasive, is not widely adopted in clinical practice, and is costly.
Computed tomography perfusion is a novel non-invasive technique that can evaluate the physiologic significance of coronary disease, and is performed by adding a single image acquisition to computed tomography in the same setting. The combination of computed tomography perfusion to computed tomography may represent an ideal "one-stop shop" that may allow for both anatomic and physiologic evaluation of coronary disease, serve as a more effective gatekeeper to cardiac catheterization, and better identify patients that would benefit from revascularization.
The emergence of dual energy computed tomography techniques enables potentially improved perfusion assessment. In particular, projection-based dual energy computed tomography is a novel computed tomography method that incorporates energy-dependent models for basis material decomposition within tissue, and may allow for absolute quantification of myocardial blood [iodine] volume with high accuracy and allows for single energy monochromatic imaging that retains image stability while reducing common computed tomography artifacts. Both of these measures by projection-based dual energy computed tomography enable quantitative assessment of myocardial iodine uptake, but the diagnostic performance of dual energy computed tomography as compared to nuclear stress testing has not been tested systematically to date.
To date, an integrated anatomic-physiologic approach by non-invasive methods has been lacking, largely due to the lack of a test that is capable of providing both accurate anatomic and physiologic data in a single setting.
The DECIDE-Gold trial will be a prospective multicenter study to evaluate the diagnostic performance of the dual energy computed tomography perfusion for the detection and exclusion of hemodynamically significant coronary artery disease, as defined by fractional flow reserve, the reference standard. The targeted population is subjects with suspected coronary artery disease who are referred for non-emergent clinically-indicated invasive coronary angiography or rest-stress nuclear imaging. The study is considered non-significant risk as investigators will be blinded to the dual energy computed tomography perfusion analyses will in no part play a role in the subject's medical treatment or clinical course.
- Conditions
- Ischemia
- Being tested
- CT and stress test
- Keywords
- Ischemia, Dual Energy Computed Tomography, Computed Tomographic Perfusion, Fractional Flow Rate, Invasive Coronary Angiography, Coronary Artery Stenosis
- Medical subject headings
- Ischemia, Coronary Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CT and stress testProcedure or surgery
Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
| Study group | Role | What they receive |
|---|---|---|
| Suspected Coronary Artery Disease | Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test Receives: Procedure: CT and stress test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy of dual energy CCTA plus perfusion (DECTP) to determine presence or absence of at least one hemodynamically (HD)-significant coronary artery stenosis* at the subject-level when compared to FFR.
Diagnostic accuracy of coronary computed tomography angiography plus dual energy computed tomographic perfusion to determine presence or absence of at least one hemodynamically-significant coronary artery stenosis at the subject level when compared to fractional flow reserve as the reference standard.
Measured: Within 60 days between CT and cath
Secondary outcomes (2)
Sensitivity, specificity, positive predictive value, and negative predictive value of coronary computed tomography angiography plus DECTP at the subject level using binary outcomes when compared to fractional flow reserve as the reference standard.
Sensitivity, specificity, positive predictive value, and negative predictive value of coronary computed tomography angiography plus dual energy computed tomographic perfusion at the subject level using binary outcomes when compared to fractional flow reserve as the reference standard.
Measured: Within 60 days between tests
Diagnostic performance (accuracy, sensitivity, specificity, PPV, and NPV) of CCTA plus DECTP for HD-significant stenosis* at the vessel-level when compared to FFR.
Diagnostic performance (sensitivity, specificity, positive predictive value, and negative predictive value) of coronary computed tomography angiography plus dual energy computed tomographic perfusion for the presence or absence of hemodynamically-significant coronary artery stenosis at the vessel level using binary outcomes when compared to fractional flow reserve as the reference standard.
Measured: Within 60 days between tests
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2014 (estimated)
- Study startMar 2014
- Primary completion8 Apr 2016
- Study completion10 Jan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IschemiaStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 156 participants (actual)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Leslee J Shaw, PhD, Principal investigator, NewYork-Presbyterian Hospital and the Weill Cornell Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02178904
- Sponsor's protocol ID
- 1309014314
- Other IDs
- R01HL111141
- Acronym
- DECIDE-Gold
- Status last verified
- Oct 2019
- First submitted
- 24 Jun 2014
- Last updated
- 16 Oct 2019
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dual Energy Computed Tomography for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques
- ClinicalTrials.gov ID
- NCT02178904
- Acronym / sponsor ID
- DECIDE-Gold / 1309014314
- Conditions
- Ischemia
- Keywords
- Ischemia, Dual Energy Computed Tomography, Computed Tomographic Perfusion, Fractional Flow Rate, Invasive Coronary Angiography, Coronary Artery Stenosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 156 participants (actual)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Mar 2014 (actual)
- Primary completion
- 8 Apr 2016 (actual)
- Study completion
- 10 Jan 2018 (actual)
- First posted
- 1 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is determine the diagnostic performance of dual energy computed tomography perfusion for non-invasive assessment of the hemodynamic significance of coronary stenosis, as compared to a direct measurement of fraction flow reserve during cardiac catheterization as a reference standard.
The overall objective of the present study is to determine the diagnostic performance of dual energy computed tomography perfusion for non-invasive assessment of the hemodynamic significance of coronary stenosis, as compared to direct measurement of fraction flow reserve during cardiac catheterization as a reference standard.
Detailed description
Coronary artery disease is the leading cause of morbidity and mortality in the United States. At present, professional guidelines endorse the use of an array of non-invasive tests for patients with suspected coronary artery disease, which are limited to one of two approaches: 1) physiologic demonstration of ischemia by functional stress testing or 2) anatomic visualization of stenosis by coronary computed tomographic angiography.
Stress test for physiologic assessment of coronary disease is performed most commonly with the prognostic value unsurpassed by other non-invasive tests, with risk of cardiac events escalating exponentially with increasing inducible hypoperfusion. However, despite its high reported performance, the "real world" accuracy of stress test is less sanguine and demonstrates generally poor discrimination of specific vessels that accommodate coronary lesions that cause ischemia. These findings have encouraged the adoption of other stress tests, such as positron emission tomography, which offers reliable attenuation correction, increased count sensitivity, lower radiation dose and enhanced diagnostic performance. Positron emission tomography also enables measures of absolute myocardial blood flow.
Coronary computed tomographic angiography is an alternative test that evaluates coronary disease by direct anatomic visualization of stenoses in a manner similar to cardiac catheterization. Similarly, when employing invasive fractional flow reserve to identify ischemia, high-grade stenoses observed by computed tomography are causal of ischemia less than half of the time.
Multicenter randomized trial data examining invasive methods have demonstrated that a combined anatomic-physiologic approach by catheterization with fractional flow reserve improves identification of patients who may benefit from revascularization, by restricting revascularization to those with high-grade stenoses that specifically cause ischemia. Nevertheless, the combination of catheterization with fractional flow reserve is invasive, is not widely adopted in clinical practice, and is costly.
Computed tomography perfusion is a novel non-invasive technique that can evaluate the physiologic significance of coronary disease, and is performed by adding a single image acquisition to computed tomography in the same setting. The combination of computed tomography perfusion to computed tomography may represent an ideal "one-stop shop" that may allow for both anatomic and physiologic evaluation of coronary disease, serve as a more effective gatekeeper to cardiac catheterization, and better identify patients that would benefit from revascularization.
The emergence of dual energy computed tomography techniques enables potentially improved perfusion assessment. In particular, projection-based dual energy computed tomography is a novel computed tomography method that incorporates energy-dependent models for basis material decomposition within tissue, and may allow for absolute quantification of myocardial blood [iodine] volume with high accuracy and allows for single energy monochromatic imaging that retains image stability while reducing common computed tomography artifacts. Both of these measures by projection-based dual energy computed tomography enable quantitative assessment of myocardial iodine uptake, but the diagnostic performance of dual energy computed tomography as compared to nuclear stress testing has not been tested systematically to date.
To date, an integrated anatomic-physiologic approach by non-invasive methods has been lacking, largely due to the lack of a test that is capable of providing both accurate anatomic and physiologic data in a single setting.
The DECIDE-Gold trial will be a prospective multicenter study to evaluate the diagnostic performance of the dual energy computed tomography perfusion for the detection and exclusion of hemodynamically significant coronary artery disease, as defined by fractional flow reserve, the reference standard. The targeted population is subjects with suspected coronary artery disease who are referred for non-emergent clinically-indicated invasive coronary angiography or rest-stress nuclear imaging. The study is considered non-significant risk as investigators will be blinded to the dual energy computed tomography perfusion analyses will in no part play a role in the subject's medical treatment or clinical course.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Suspected Coronary Artery Disease | – | Procedure: CT and stress testSubjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Hospitals in Argentina, Beijing, Seattle, Vancouver, New York
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Patients provide written informed consent
- Patients scheduled to undergo clinically-indicated non-emergent invasive coronary angiography
- suspected coronary artery disease
Key exclusion criteria (10 listed)
- Suspicion of acute coronary syndrome (acute myocardial infarction and unstable angina)
- Recent prior myocardial infarction within 40 days of ICA
- Known complex congenital heart disease
- Significant arrhythmia or tachycardia
- Impaired chronic renal function (serum creatinine > 1.5 mg/dl or GFR < 30 ml/min)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CT and stress testCoronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP) | Procedure or surgery | Suspected Coronary Artery Disease |
Primary outcome
Diagnostic accuracy of dual energy CCTA plus perfusion (DECTP) to determine presence or absence of at least one hemodynamically (HD)-significant coronary artery stenosis* at the subject-level when compared to FFR.
Time frame: Within 60 days between CT and cath
Diagnostic accuracy of coronary computed tomography angiography plus dual energy computed tomographic perfusion to determine presence or absence of at least one hemodynamically-significant coronary artery stenosis at the subject level when compared to fractional flow reserve as the reference standard.
2 secondary outcomes
Sensitivity, specificity, positive predictive value, and negative predictive value of coronary computed tomography angiography plus DECTP at the subject level using binary outcomes when compared to fractional flow reserve as the reference standard.
Time frame: Within 60 days between tests
Diagnostic performance (accuracy, sensitivity, specificity, PPV, and NPV) of CCTA plus DECTP for HD-significant stenosis* at the vessel-level when compared to FFR.
Time frame: Within 60 days between tests
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Ischemia
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leslee J Shaw, PhD principal investigator
NewYork-Presbyterian Hospital and the Weill Cornell Medical College
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemia, run by Weill Medical College of Cornell University at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic accuracy of dual energy CCTA plus perfusion (DECTP) to determine presence or absence of at least one hemodynamically (HD)-significant coronary artery stenosis* at the subject-level when compared to FFR. (time frame: Within 60 days between CT and cath). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2019.